Loading...
•
Mar 31, 2024
United Therapeutics Q1 2024 Earnings Report
United Therapeutics reported record revenue and double-digit year-over-year revenue growth.
Key Takeaways
United Therapeutics reported a 34% increase in total revenues to $677.7 million for Q1 2024, compared to $506.9 million in Q1 2023. Net income increased by 27% to $306.6 million. The company also implemented a $1 billion accelerated share repurchase program.
Total revenues grew by 34% year-over-year to $677.7 million.
Net income increased by 27% to $306.6 million.
Tyvaso revenues increased by 56% to $372.5 million.
Implemented a $1 billion accelerated share repurchase program.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
United Therapeutics Revenue by Geographic Location
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
United Therapeutics did not provide specific forward guidance in this earnings report. The report highlights the company's revenue growth, clinical catalysts, and potential for organ manufacturing.
Positive Outlook
- Solid and growing commercial foundation.
- Near-term clinical catalysts.
- Potential to provide an unlimited supply of tolerable, transplantable organs.
- Solid balance sheet.
- Strong cash flow potential.
Challenges Ahead
- Potential competition emerging this year.
- Risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission.
- Impact of potential competition on near-term and long-term potential.
- No specific financial guidance provided.
- Dependence on regulatory approvals and clinical trial outcomes.
Revenue & Expenses
Visualization of income flow from segment revenue to net income